Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva and Radiotherapy in Locally Advanced NSCLC
NCT00888511Phase 2Completed
- Start
- May 2009
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC). Primary endpoint: Progression Free Survival at 3 years. Started May 2009; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00888511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00888511.